Business Description
Tarsus Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US87650L1035
Share Class Description:
TARS: Ordinary SharesTotal Employee Number:
370Description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.18 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -2.52 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.69 | |||||
Beneish M-Score | -2.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 117.6 | |||||
3-Year EBITDA Growth Rate | 18.8 | |||||
3-Year EPS without NRI Growth Rate | 13.9 | |||||
3-Year FCF Growth Rate | 35.7 | |||||
3-Year Book Growth Rate | 3.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 33.91 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.09 | |||||
9-Day RSI | 62.26 | |||||
14-Day RSI | 62.31 | |||||
3-1 Month Momentum % | -0.99 | |||||
6-1 Month Momentum % | -21.94 | |||||
12-1 Month Momentum % | 1.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.2 | |||||
Quick Ratio | 3.17 | |||||
Cash Ratio | 2.56 | |||||
Days Inventory | 37.68 | |||||
Days Sales Outstanding | 49.65 | |||||
Days Payable | 267.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.28 | |||||
Operating Margin % | -8.01 | |||||
Net Margin % | -7.67 | |||||
EBITDA Margin % | -4.76 | |||||
FCF Margin % | 9.24 | |||||
OCF Margin % | 12.23 | |||||
ROE % | -13.61 | |||||
ROA % | -8.35 | |||||
ROIC % | -88.44 | |||||
3-Year ROIIC % | -14.16 | |||||
ROC (Joel Greenblatt) % | -155.07 | |||||
ROCE % | -7.36 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 106.36 | |||||
Price-to-Owner-Earnings | 140.21 | |||||
PS Ratio | 5.09 | |||||
PB Ratio | 8.96 | |||||
Price-to-Tangible-Book | 9.15 | |||||
Price-to-Free-Cash-Flow | 55.44 | |||||
Price-to-Operating-Cash-Flow | 41.81 | |||||
EV-to-EBIT | -88.85 | |||||
EV-to-EBITDA | -96.05 | |||||
EV-to-Revenue | 4.57 | |||||
EV-to-Forward-Revenue | 3.9 | |||||
EV-to-FCF | 49.52 | |||||
Price-to-GF-Value | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 10.43 | |||||
| Price-to-Net-Cash | 16.77 | |||||
Earnings Yield (Greenblatt) % | -1.13 | |||||
FCF Yield % | 1.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TARS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tarsus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 606.331 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 0.4733 | ||
| 3-Year Sharpe Ratio | 0.74 | ||
| 3-Year Sortino Ratio | 1.5 | ||
| Volatility % | 64.48 | ||
| 14-Day RSI | 62.31 | ||
| 14-Day ATR ($) | 2.704787 | ||
| 20-Day SMA ($) | 68.85275 | ||
| 12-1 Month Momentum % | 1.36 | ||
| 52-Week Range ($) | 48.2 - 85.25 | ||
| Shares Outstanding (Mil) | 43.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tarsus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tarsus Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 16:30 | In 179 days | ||
| Annual report for 2026 | 2027-02-23 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 178 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | 61.29 (-1.18%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 61.29 (-1.18%) | ||
| Tarsus Acquires iRenix | 2026-07-08 16:30 | 70.55 (+3.17%) | ||
| General meeting for 2026 | 2026-06-25 09:00 | 67.11 (+1.07%) | ||
| Guidance call for 2026 | 2026-06-03 08:40 | 57.41 (-1.39%) |
Show
Entries
Tarsus Pharmaceuticals Inc Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc(TARS)'s stock price today?
The current price of TARS is $71.79. The 52 week high of TARS is $85.25 and 52 week low is $48.20.
When is next earnings date of Tarsus Pharmaceuticals Inc(TARS)?
The next earnings date of Tarsus Pharmaceuticals Inc(TARS) is 2026-11-04 Est..
Does Tarsus Pharmaceuticals Inc(TARS) pay dividends? If so, how much?
Tarsus Pharmaceuticals Inc(TARS) does not pay dividend.
Guru Commentaries on NAS:TARS
2026 Q2
6a6237b88379628c04d2479f TimesSquare U.S. Small Cap Growth 2Q26 Commentary
What the manager wrote
Tarsus Pharmaceuticals, a commercial-stage company focused on eye care, declined -10% despite continued commercial progress for its demodex blepharitis treatment, XDEMVY. While actual script volume continues to track well above consensus, the stock contracted during the period as the market prematurely priced in a potential competitor that is years away and gated by an untested ocular-tolerability profile.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Summit Materials, Informatica, Unicycive Therapeutics, Tarsus Pharmaceuticals, or Zion Oil and Gas? | 2024-02-29 |
Articles on Tarsus Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers